Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05553938 | Recruiting | Heart Failure

Effects of Acute and Chronic Empagliflozin Heart Failure
Sponsor:

Yale University

Brief Summary:

This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.

Condition or disease

Heart Failure

Intervention/treatment

Empagliflozin 10 mg

Placebo

Phase

Phase 1

Detailed Description:

This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. The broad study design aims to evaluate change in gold standard determined body fluid spaces, sodium avidity, and cardio-renal biomarkers longitudinally in patients treated with placebo vs. empagliflozin over a 6 week period. Primary analysis of the randomized intervention will occur during the 6 week double blind period. Crossover of placebo patients to active therapy from 6-12 weeks will provide additional exploratory mechanistic data at low incremental cost and provide added benefit to enrollment of the study.}}

Study Type : Interventional
Estimated Enrollment : 60 participants
Masking : Triple
Masking Description : Double-blind
Primary Purpose : Other
Official Title : Renal Mechanistic Effects of Acute and Chronic Empagliflozin in Heart Failure
Actual Study Start Date : August 4, 2023
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : November 2024
Arm Intervention/treatment

Experimental: Empagliflozin

Empagliflozin 10 mg daily for weeks 1-6

Drug: Empagliflozin 10 mg

Experimental: Placebo, Then Empagliflozin

Participants first receive matching placebo daily for weeks 1-6, then will receive Empagliflozin 10 mg daily for weeks 7-12

Drug: Empagliflozin 10 mg
Ages Eligible for Study: 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • A clinical diagnosis of worsening heart failure (worsening of congestive symptoms with current therapies) in the opinion of the investigator.
  • A planned outpatient diuretic intervention (either up-titration of loop or addition of thiazide diuretic) for worsening heart failure per treating clinician. Diuretic intervention can occur via an unplanned in person visit (e.g., outpatient ambulatory clinic, emergency department, same day access visit) or via a telephone encounter (e.g., patient calling the clinic with reported weight gain and SOB that is prescribed uptitration of diuretic therapy).
  • Estimated or reported weight gain of at least 5 lbs.
  • Chronic daily oral loop diuretic dose ≥ 20mg furosemide equivalents for at least one month prior to enrollment
  • Estimated GFR (eGFR) ≥ 20 mL/min/1.73 m2
  • Age ≥ 18 years old
  • Signed informed consent
  • English speaking participants only
Exclusion Criteria
  • Need for heart failure hospitalization at the time of randomization
  • Current use or plan to initiate renal replacement therapy
  • Significant bladder dysfunction or urinary incontinence
  • Inability to comply with the serial urine collection procedures
  • Chronic use of natriuretic doses of thiazide diuretics (≥50mg hydrochlorothiazide or equivalent)
  • Critical stenotic valvular disease, complex congenital heart disease or prior heart transplant
  • History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months
  • History of or current urosepsis or frequent urinary tract infections
  • Anemia with hemoglobin <8g/dL (due to required phlebotomy for the study) or active bleeding
  • Pregnancy or breastfeeding
  • Appears unlikely or unable to participate in the required study procedures, as assessed by the study PI, study coordinator, or designee (ex: clinically-significant psychiatric, addictive, or neurological disease)
Effects of Acute and Chronic Empagliflozin Heart Failure

Location Details

Please Choose a site

Effects of Acute and Chronic Empagliflozin Heart Failure

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Recruiting

United States, Connecticut

Yale New Haven Hospital

New Haven, Connecticut, United States, 06520

Recruiting

United States, Connecticut

Yale University

New Haven, Connecticut, United States, 06520